KLRS vs KURA

Kalaris Therapeutics, Inc. vs Kura Oncology, Inc. — Valuation Comparison 2026

KLRS

Biotechnology
Kalaris Therapeutics, Inc.
Quality
4.1
out of 10
Value Trap
30
LOW
Price
$5.18
Last close
Models
7/13
Active
VS

KURA

Biotechnology
Kura Oncology, Inc.
Quality
5.6
out of 10
Value Trap
12
SAFE
Price
$9.97
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType KLRS Fair ValueKLRS Upside KURA Fair ValueKURA Upside
Bayesian DCF Intrinsic $0.45 -91.4% $2.83 -71.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.17 -77.3% $1.03 -89.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for KLRS vs KURA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

KLRS vs KURA — Which Stock Is More Undervalued?

KURA scores higher with a 5.6/10 quality rating vs KLRS's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Kalaris Therapeutics, Inc. (KLRS) and Kura Oncology, Inc. (KURA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

KLRS currently trades at $5.18 with a QOC of 4.1/10, while KURA trades at $9.97 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).